An observational study in Soft Tissue Neoplasm, Soft Tissue Sarcoma and Soft Tissue Mass, sponsored by Istituto Ortopedico Rizzoli. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2023-05-23.
Sponsored by Istituto Ortopedico Rizzoli · Observational
A retrospective evaluation of soft tissue tumors that have undergone core needle biopsy with US guidance (US-CNB)
The present study is designed to be the first step in the creation of an interdisciplinary platform collecting data on patients and procedures to provide a predictive tool to help physicians in the management of patients affected by a soft tissue lesion.
The primary aim of our work is to evaluate the diagnostic yield of US-CNB. The secondary aim is to exploit all the imaging data conventionally available at a Sarcoma Center before a biopsy on a soft tissue mass, to build a multiparametric model and score of prediction of malignancy, and eventually of biological behavior - grading.
38 studies on the registry are indexed under Soft Tissue Neoplasms; 14 are open to participants now.
This study's enrollment of 350 is above the median of 113 across 18 observational studies indexed under Soft Tissue Neoplasms.
Browse Soft Tissue Neoplasms studies →Istituto Ortopedico Rizzoli is the lead sponsor of 304 studies on the registry; 103 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will enroll 350 patients who underwent US-CNB for soft tissue lesion at the Rizzoli Orthopaedic Institute
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic yield
Diagnostic yield will be defined as the number of diagnostic core needle biopsies divided by the total number of core needle biopsies. A diagnostic yield \> 94% will be considered sufficient to produce a sample to reach the histological diagnosis.
Time frame: One year
Prediction of malignancy
To determine which imaging features and biomarkers correlates with malignancy and biological behavior of soft tissue masses.
Time frame: One year
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2018 to primary completion in Jan 2019, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.